8 results about "Appetite Suppression" patented technology

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

The invention provides a process for preparing a plasticised superporous hydrogel material comprising subjecting initial hydrogel material to treatment with an acidic solution, an optional treatment with a monovalent metal salt solution, freeze drying and plasticisation. Optionally, the process of the invention produces moulded plasticised superporous hydrogel material bodies that have one or more through-holes formed therein. The plasticised superporous hydrogel material of the present invention may be formulated as a suitable oral dosage form for use an appetite suppressant and for use to deliver a pharmaceutical and / or nutraceutical into a human or animal body.

The present invention discloses a guarana extract – EGCG synergistic fat-burning composition, belonging to the technical field of functional foods and weight management. The composition comprises guarana extract, epigallocatechin gallate, and konjac glucomannan. By controlling the component ratio and key parameters, a dynamic gel network formed by konjac glucomannan provides in-situ protection of active ingredients and enables programmed release in the gastrointestinal tract, while constructing a multi-level appetite-suppression system with temporal continuity.The invention overcomes problems in the prior art, including poor stability, low bioavailability, and fragmented appetite regulation, and achieves synergistic effects in fat burning and intake control. It is suitable for preparing oral solid formulations, with high safety, good stability, and suitability for large-scale industrial production and commercialization.

The present application relates to the technical field of bioactive peptides, and in particular to an oat oligopeptide, preparation thereof and application thereof in preparing a product for regulating the expression of brain appetite suppressor factor. The oat oligopeptide can effectively stimulate the release of cholecystokinin (CCK) from intestinal endocrine cells, and stimulate the central nervous system through the vagus nerve pathway, thereby promoting the expression of the appetite suppressor factor pro-opiomelanocortin (POMC) in the hypothalamus. Compared with the prior art, the oat oligopeptide has the advantages of stable structure, high safety, simple preparation process (conventional enzymatic hydrolysis and chromatographic purification can achieve the preparation), easy scale production and the like. The oat oligopeptide is suitable for being used as a functional ingredient or a drug precursor to develop a related health product with the functions of regulating appetite and promoting satiety, and has a wide application prospect in the field of preparing functional products (food, medicine and the like).

The present application provides a soluble dietary fiber composition, its preparation method and application. After the soluble dietary fiber composition enters the colon, the ester bond in the alanine modified pectin is rapidly degraded, part of the chlorogenic acid is released, the secretion of anorectic hormone is stimulated, the appetite is reduced, and the heat intake is reduced; the remaining amide bond network is slowly degraded, realizing the slow and continuous release of chlorogenic acid. Lutein removes free radicals generated by fat decomposition, reducing the oxidative damage of L cells. Galactomannan and alanine modified pectin-glucan modified protein-chlorogenic acid ternary complex synergize to improve the molar ratio of butyric acid / propionic acid: propionic acid enhances satiety through intestinal gluconeogenesis, and butyric acid stimulates the secretion of GLP-1 / PYY, realizing endogenous appetite suppression. Galactomannan absorbs water to form a lubricating gel, softening the stool and increasing the stool volume; the ternary complex degrades to produce short-chain fatty acids, optimizing the intestinal microenvironment and enhancing gastrointestinal peristalsis, both of which synergistically improve constipation.

The application discloses a kind of guanara extract-EGCG synergistic fat-burning slimming composition, it relates to the technical field of functional food and weight management.The composition is composed of guanara extract, epigallocatechin gallate and konjac glucomannan, by limiting the weight ratio of each component and key performance parameter, using the dynamic gel network formed by konjac glucomannan, realize the in-situ physical protection and whole digestive tract programmed release of active ingredients, and build a multi-level coherent and connected appetite suppression system.The application solves the technical problems of poor stability of active ingredients, low bioavailability and fragmented appetite regulation mechanism in the prior art, can realize the deep synergy of fat-burning and food control, can be used for preparing weight management related oral solid preparations, has high safety, is suitable for industrial large-scale production and market promotion and application.

Disclosed herein is the use of N6-benzylaminopurine (BAP) as an appetite suppressant in animals including humans. The results of studies demonstrate the use of BAP as an appetite suppressant in animals, and the use of this common agricultural supplement for plant growth can be used to help to alleviate the ever-growing obesity pandemic afflicting modern society.

The present invention relates to a spray that suppresses the user's appetite (bulimia) immediately and gives him a feeling of fullness so that he is not forced to eat a snack of any kind to deal with the feeling of hunger. The present invention contains chromium, French Lilac Extract, tyrosine, nicotinamide adenine dinucleotide (NAD), berberine, tryptophan, eggplant extract and has the flavor of vanilla, mint, banana, green apple, avocado, cinnamon and grapefruit. Its use is simple, pleasant and completed in two or three sprays into the mouth.